CN Patent

CN106279171A — 一种Idelalisib的制备方法

Assigned to Nanjing Anyuan Bio-Pharmaceutical Technology Co Ltd · Expires 2017-01-04 · 9y expired

What this patent protects

本发明属于医药化工领域,具体而言涉及一种Idelalisib的制备方法。本发明的制备方法,通过在六甲基二硅胺和碘存在下,(S)‑N‑[2‑[[3‑氟‑2‑[(苯基氨基)羰基]苯基]氨基]‑1‑乙基‑2‑氧代乙基]‑氨基甲酸叔丁酯进行反应制备关键中间体(S)‑2‑(1‑氨基‑丙基)‑5‑氟‑3‑苯基‑3H‑喹唑啉‑4‑酮,再进行两步反应最终得到Idelalisib,本发明反应试剂容易获得,反应条件温和,操作简便易制备,生产效率高,所制备的中间体及产品均具有高收率和高纯度,且与现有技术相比,不容易产生杂质。因此,本发明的制备方法特别适应工业化生产。

USPTO Abstract

本发明属于医药化工领域,具体而言涉及一种Idelalisib的制备方法。本发明的制备方法,通过在六甲基二硅胺和碘存在下,(S)‑N‑[2‑[[3‑氟‑2‑[(苯基氨基)羰基]苯基]氨基]‑1‑乙基‑2‑氧代乙基]‑氨基甲酸叔丁酯进行反应制备关键中间体(S)‑2‑(1‑氨基‑丙基)‑5‑氟‑3‑苯基‑3H‑喹唑啉‑4‑酮,再进行两步反应最终得到Idelalisib,本发明反应试剂容易获得,反应条件温和,操作简便易制备,生产效率高,所制备的中间体及产品均具有高收率和高纯度,且与现有技术相比,不容易产生杂质。因此,本发明的制备方法特别适应工业化生产。

Drugs covered by this patent

Patent Metadata

Patent number
CN106279171A
Jurisdiction
CN
Classification
Expires
2017-01-04
Drug substance claim
No
Drug product claim
No
Assignee
Nanjing Anyuan Bio-Pharmaceutical Technology Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.